ENANTA PHARMACEUTICALS INC's ticker is ENTA and the CUSIP is 29251M106. A total of 122 filers reported holding ENANTA PHARMACEUTICALS INC in Q2 2017. The put-call ratio across all filers is 0.66 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2019 | $84,000 | -61.8% | 1,000 | -56.5% | 0.00% | -66.7% |
| Q1 2019 | $220,000 | -36.6% | 2,300 | -53.1% | 0.01% | -42.9% |
| Q4 2018 | $347,000 | -20.4% | 4,900 | -3.9% | 0.02% | -4.5% |
| Q3 2018 | $436,000 | -30.4% | 5,100 | -5.6% | 0.02% | -33.3% |
| Q2 2018 | $626,000 | -28.4% | 5,400 | -50.0% | 0.03% | -31.2% |
| Q1 2018 | $874,000 | +37.9% | 10,800 | 0.0% | 0.05% | +41.2% |
| Q4 2017 | $634,000 | -32.3% | 10,800 | -46.0% | 0.03% | -33.3% |
| Q3 2017 | $936,000 | +25.6% | 20,000 | -3.4% | 0.05% | +21.4% |
| Q2 2017 | $745,000 | -1.3% | 20,700 | -15.5% | 0.04% | -2.3% |
| Q1 2017 | $755,000 | -5.3% | 24,500 | +2.9% | 0.04% | -12.2% |
| Q4 2016 | $797,000 | +310.8% | 23,800 | +170.5% | 0.05% | +276.9% |
| Q3 2016 | $194,000 | 0.0% | 8,800 | 0.0% | 0.01% | 0.0% |
| Q2 2016 | $194,000 | – | 8,800 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Consonance Capital Management LP | 1,546,097 | $66,590,000 | 9.91% |
| RA Capital Management | 1,539,586 | $66,310,000 | 6.70% |
| SENZAR ASSET MANAGEMENT, LLC | 255,128 | $10,988,000 | 4.20% |
| INSIGHT CAPITAL RESEARCH & MANAGEMENT INC | 158,315 | $6,819,000 | 1.56% |
| Sarissa Capital Management LP | 105,000 | $4,522,000 | 1.54% |
| Ghost Tree Capital, LLC | 50,000 | $2,154,000 | 1.52% |
| BENNETT LAWRENCE MANAGEMENT L L C/NY | 118,445 | $5,102,000 | 0.90% |
| WALL STREET ASSOCIATES | 219,200 | $9,441,000 | 0.81% |
| Granite Point Capital Management, L.P. | 25,000 | $1,077,000 | 0.74% |
| BAILARD, INC. | 91,500 | $3,941,000 | 0.61% |